Aytu BioPharma (AYTU) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $14.50 from $14.00 | Jun 11, 2026 |
| Ascendiant Capital | Maintained | Buy | $13.00 from $12.50 | Dec 10, 2025 |
| Ascendiant Capital | Maintained | Buy | $12.50 from $12.00 | Sep 25, 2025 |
| Maxim Group | Maintained | Buy | $7.00 from $9.00 | Sep 25, 2025 |
| Lake Street | Initiated Coverage | Buy | $8.00 | Jul 1, 2025 |
| Ascendiant Capital | Initiated Coverage | Buy | $12.00 | Jun 30, 2025 |
| Maxim Group | Initiated Coverage | Buy | $5.00 | Aug 9, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | May 31, 2023 |
Frequently asked questions
Is AYTU a buy, sell, or hold?
Analysts covering Aytu BioPharma currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on AYTU?
On Jun 11, 2026, Ascendiant Capital maintained Aytu BioPharma at Buy with a price target of $14.50.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.